RE: Webinar18 Jul 2025 12:09
Owns 2 clinical tests on the markets with reimbursement codes with coverage by either Medicare or in the States or, for example, Bupa in U.K.
We're also following up, and I will cover a little bit on the new products coming out of pipeline related to multi-choice multi-cancer detection, very important development. The test for colorectal cancer and polyps which, along with the prostate cancer addresses the most urgent utility of false positives in early screening and detection and also some of the work we've done successfully for Mitsubishi Tanabe in United States for the drug, which is today approved for motor neurone disease, ALS RADICAVA.